<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gallium citrate Ga-67: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gallium citrate Ga-67: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Gallium citrate Ga-67: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="17076" href="/d/html/17076.html" rel="external">see "Gallium citrate Ga-67: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F53522206"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Gallium</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F13176404"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Radiopharmaceutical</li></ul></div>
<div class="block doa drugH1Div" id="F13176473"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a242dd7a-63e5-444d-b313-c1b0fb21c573">Diagnostic imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Diagnostic imaging:</b>
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Scintigraphy for inflammation or infection: 4 to 6 mCi (150 to 220 MBq) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Tumor scintigraphy: 5 to 10 mCi (185 to 370 MBq) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Manufacturer's labeling: Dosing in the prescribing information may not reflect current clinical practice. (Based on 70 kg patient): 2 to 5 mCi (74 to 185 MBq).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990522"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50987829"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F55799536"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing; use with caution and consider starting at lower end of dosage range.</p></div>
<div class="block dop drugH1Div" id="F13176472"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a242dd7a-63e5-444d-b313-c1b0fb21c573">Diagnostic imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnostic imaging:</b> Scintigraphy for inflammation or infection (off-label use): IV: 0.07 mCi/kg (2.6 MBq/kg), with a minimum of 0.5 mCi (18.5 MBq) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.1'])">Ref</a></span>) <b>or </b>alternatively for children &gt;5 years: 0.04 to 0.07 mCi/kg (1.5 to 2.6 MBq/kg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Palestro.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Palestro.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51112272"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block dohp drugH1Div" id="F51112273"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F13176476"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin, pruritus, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p></div>
<div class="block coi drugH1Div" id="F25593625"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the US manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to gallium citrate or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F13176406"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special handling: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and health care personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other Warnings/Precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: The finding of an abnormal gallium Ga-67 concentration usually implies the existence of underlying pathology, but further diagnostic studies should be done to distinguish benign from malignant lesions. Use is intended as an adjunct in the diagnosis of certain neoplasms as well as focal areas of infection. Certain pathologic conditions may yield up to 40% false-negative gallium Ga-67 studies; a negative study cannot be definitely interpreted as ruling out the presence of disease. Lymphocytic lymphoma frequently does not accumulate gallium Ga-67 sufficiently for unequivocal imaging, and the use of gallium with this histologic type of lymphoma is not recommended at this time. Gallium Ga-67 localization cannot differentiate between tumor and acute inflammation, and other diagnostic studies must be added to define the underlying pathology.</p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP 1997; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer’s labeling. Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: The vial stopper may contain natural rubber latex.</p></div>
<div class="block foc drugH1Div" id="F53390084"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as citrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mCi/mL (1 ea [DSC])</p></div>
<div class="block geq drugH1Div" id="F53390083"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F53559972"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Gallium Citrate Ga 67 Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mci/mL (per each): $1,069.39 - $3,208.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F53522207"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as citrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mCi/mL (3 mL, 6 mL)</p></div>
<div class="block adm drugH1Div" id="F20217923"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> For IV administration. Time to obtain images after administration may vary based on procedure (from hours to days); refer to manufacturer's labeling and/or specific procedure guidelines for recommendations. Radiopharmaceutical; use appropriate precautions for handling and disposal. Use waterproof gloves and effective radiation shielding when handling.</p>
<p style="text-indent:0em;margin-top:2em;">The manufacturer recommends administration of daily laxatives and/or enemas during the first week after injection until final images are obtained to cleanse the bowel of radioactive material and to minimize false positive results.</p></div>
<div class="block admp drugH1Div" id="F52614174"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Radiopharmaceutical; use appropriate precautions for handling and disposal. Use waterproof gloves and effective radiation shielding when handling.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: For IV administration only. The manufacturer recommends administration of daily laxatives and/or enemas during the first week after injection and until final images are obtained to cleanse the bowel of radioactive material and to minimize false positive results.</p></div>
<div class="block use drugH1Div" id="F13176405"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Diagnostic imaging:</b> Diagnostic imaging agent for use in identifying the presence and extent of Hodgkin disease, lymphoma, bronchogenic carcinoma, and acute inflammatory lesions </p></div>
<div class="block mst drugH1Div" id="F13255250"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Gallium Citrate Ga-67 may be confused with Gallium Ga 68 Dotatate, Gallium Ga 68 PSMA-11.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F56723911"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F56723908"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Deferoxamine: May diminish the diagnostic effect of Gallium Citrate Ga-67. Management: Discontinue deferoxamine 48 hours prior to scintigraphy with gallium citrate Ga-67.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53559935"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">The manufacturer recommends that when elective procedures are conducted in women of reproductive potential, they should be done within the first 10 days of menses.</p></div>
<div class="block pri drugH1Div" id="F13176453"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Ga 67 can accumulate in the placenta (Kurosak 2001; Newman 1978; Palestro 1986).</p></div>
<div class="block brc drugH1Div" id="F13176455"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Ga 67 accumulates in the breast even in nonlactating patients (Hor 1976). Significant concentrations were detected in the breast milk of one postpartum woman 10 days after dosing (Hoffer 1977). The actual concentration may depend on volume of milk flow and stage of breastfeeding (Tobin 1976). The manufacturer recommends to substitute formula for breast milk. Due to the long half-life of Ga 67, one guideline recommends discontinuing breastfeeding for at least 2 to 4 weeks after the injection in order to reduce exposure to the breastfeeding infant (Palestro 2004).</p></div>
<div class="block pha drugH1Div" id="F46023658"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Gallium citrate Ga-67 is a radioactive diagnostic agent which accumulates in lysosomes and is bound to a soluble intracellular protein. It has been found to concentrate in certain viable primary and metastatic tumors as well as focal sites of infections.</p></div>
<div class="block phk drugH1Div" id="F46023659"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Physical: 78.3 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: After 7 days: Average whole body retention 65%, urine 26%, feces 9%</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58203628"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Gallium citrate</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Citrato de galio (67 Ga)</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Gallium citrate</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Gallium citrate</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Citrato de galio (67Ga) CIS bio international</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Citrate de gallium (67ga) cis bio internation</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Gallium citrate abbott | Gallium citrate amersh | Gallium citrate daiichi r.i.c | Gallium citrate nihon</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Citrato de galio (67 Ga)</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Gallium citrate 67Ga</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gallium-citrate-ga-67-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACR.1">
<a name="ACR.1"></a>American College of Radiology, Society for Pediatric Radiology. ACR-SPR Practice Parameter for the Performance of Scintigraphy for Inflammation and Infection. Resolution 28. https://www.acr.org/-/media/ACR/Files/Practice-Parameters/inflaminfscint.pdf?la=en. Revised 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACR.2">
<a name="ACR.2"></a>American College of Radiology, Society for Pediatric Radiology. ACR-SPR Practice Parameter for the Performance of Tumor Scintigraphy (With Gamma Cameras). Resolution 48. http://www.acr.org/~/media/921761B083FE4457A9121953D080BA1C.pdf. Revised 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol--United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gallium-citrate-ga-67-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Gallium Citrate Ga 67 [prescribing information]. N. Billerica, MA: Lantheus Medical Imaging; March 2018.</div>
</li>
<li>
<div class="reference">
                  Gallium Citrate Ga 67 [product monograph]. Laval, Quebec, Canada: Curium Canada Inc; April 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>.1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gallium-citrate-ga-67-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-267143">
<a name="267143"></a>Hoffer PB, Huberty J, Khayam-Bashi H. The association of Ga-67 and lactoferrin. <i>J Nucl Med</i>. 1977;18(7):713-717.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gallium-citrate-ga-67-drug-information/abstract-text/267143/pubmed" id="267143" target="_blank">267143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1249634">
<a name="1249634"></a>Hör G, Heidenreich P, Kriegel H, et al. Letter: Breast scintigraphy with 99mTc-pertechnetate and 67Ga-citrate. <i>J Nucl Med</i>. 1976;17(3):223.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gallium-citrate-ga-67-drug-information/abstract-text/1249634/pubmed" id="1249634" target="_blank">1249634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11545204">
<a name="11545204"></a>Kurosaki H, Saito Y, Kawashima M, et al. Accumulation of 67Ga citrate in early pregnancy. <i>Ann Nucl Med</i>. 2001;15(3):289-291.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gallium-citrate-ga-67-drug-information/abstract-text/11545204/pubmed" id="11545204" target="_blank">11545204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-580436">
<a name="580436"></a>Newman RA, Gallagher JG, Clements JP, et al. Demonstration of Ga-67 localization in human placenta. <i>J Nucl Med</i>. 1978;19(5):504-506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gallium-citrate-ga-67-drug-information/abstract-text/580436/pubmed" id="580436" target="_blank">580436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Palestro.1">
<a name="Palestro.1"></a>Palestro CJ, Brown ML, Forstrom LA, et al, “Society of Nuclear Medicine Procedure Guideline for Gallium Scintigraphy in Inflammation," 2004. Available at http://interactive.snm.org/docs/Gallium_Scintigraphy_in_Inflammation_v3.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2940348">
<a name="2940348"></a>Palestro CJ, Malat J, Collica CJ, et al. Incidental diagnosis of pregnancy on bone and gallium scintigraphy. <i>J Nucl Med</i>. 1986;27(3):370-372.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gallium-citrate-ga-67-drug-information/abstract-text/2940348/pubmed" id="2940348" target="_blank">2940348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-993836">
<a name="993836"></a>Tobin RE, Schneider PB. Uptake of 67Ga in the lactating breast and its persistence in milk: case report. <i>J Nucl Med</i>. 1976;17(12):1055-1056.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gallium-citrate-ga-67-drug-information/abstract-text/993836/pubmed" id="993836" target="_blank">993836</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 16796 Version 79.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
